Immutep Ltd · ASX:IMM
Immutep — Investor Presentation (March 2023)
27 slides from Immutep's investor presentation, March 2023
Slide 1: Unlocking the power of the immune system against cancer and autoimmune disease
Unlocking the power of the immune system against cancer and autoimmune disease. I Corporate Presentation – March 2023 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Forward-Looking Statements
Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarificati
Slide 3: Immutep Highlights
Immutep Highlights Novel science and Compelling Validation through Global presence; Substantial market Key catalysts advanced pipeline clinical data partnerships strong balance sheet opportunity ahead Pioneering LAG-3 First-in-class eftilagimod Multiple partnerships & Global presence and Efti has sa
Slide 4: Pipeline
Pipeline Program Indication Preclinical Phase I Phase II Late Stage* Collaborations Commercial Rights 1L Head & Neck Squamous Cell Carcinoma (HNSCC) TACTI-003 | Efti+Pembrolizumab a 1L Non-Small Cell Lung Cancer (NSCLC), Eftilagimod Alpha 2L HNSCC, PD-X Refractory 2L NSCLC TACTI-002 | Efti+Pembroliz
Slide 5: Immuno-Oncology
Immuno-Oncology Our immune systems naturally protect us against cancer, yet cancers are adept at hiding to protect themselves. Cancer immunotherapy or Immuno-Oncology (IO) reverses that and restores the power of patients’ own immune systems to prevent, control, and eliminate cancer. Today, IO is the
Slide 6: Empowering the Immune System to Fight Cancer with a First-in-Class Immunotherapy
Empowering the Immune System to Fight Cancer with a First-in-Class Immunotherapy Eftilagimod alpha’s unlocking of broad immune system activation to fight cancer… Subcutaneous injection of Activated Efti Eftilagimod alpha (efti) APCs T Cells NK Cells Dendritic Cells Monocytes IFN-ƴ CXCL10 MHC II (CD8
Slide 7: Pipeline in a Product
Pipeline in a Product Efti Clinical Trials Confirm Broad Potential Preclinical Phase I Phase II Late Stage* 1st Line Head & Neck Squamous Cell Carcinoma (HNSCC) Efti + Pembrolizumab a 1st Line Non-Small Cell Lung Cancer (NSCLC), 2nd Line Efti + Pembrolizumab a HNSCC, PD-X Refractory 2nd Line NSCLC I
Slide 8: Substantial Commercial Opportunity
Substantial Commercial Opportunity Efti's ability to safely improve clinical outcomes across the entire PD-L1 spectrum in multiple solid tumors* may substantially expand the addressable patient populations for chemotherapy-free IO/IO combinations. Efti + Anti-PD-(L)1 Anti-PD-1 Anti-PD-L1 • Doubled O
Slide 9: 1st Line Non-Small Cell Lung Cancer (1L NSCLC)
1st Line Non-Small Cell Lung Cancer (1L NSCLC) *SITC 2022 – Dr. Wade Iams presenting 1L NSCLC data from *ASCO 2022 - Dr. Enriqueta Felip presenting 1L NSCLC data TACTI-002/KEYNOTE-798 in Late Breaking Abstract Oral from TACTI-002/KEYNOTE-798 in Oral Presentation Presentation 9
Slide 10: Treatment Options in 1L NSCLC Limited by Durability & Tolerability
Treatment Options in 1L NSCLC Limited by Durability & Tolerability 1L NSCLC Epidemiology1,2 – 1.87 million NSCLC diagnoses per annum – NSCLC is the highest cause of death among all cancers – Immutep is focused on improving clinical responses for the 1.3 million patients that develop metastatic disea
Slide 11: PD-L1 Expression Matters in Solid Tumors such as 1L NSCLC
PD-L1 Expression Matters in Solid Tumors such as 1L NSCLC from Treatment & Addressable Patient Population Perspective 1L NSCLC Patient Population by PD-L1 Tumor Proportion Score (TPS) Score* TPS Score of >50% represents ~30% of 1L TPS Score of 1-49% or lower represents ~35% TPS Score of <1% or lower
Slide 12: Phase II All-Comer PD-L1 Trial Evaluating Efti + Pembrolizumab in 1L NSCLC
Phase II All-Comer PD-L1 Trial Evaluating Efti + Pembrolizumab (KEYTRUDA®) in 1L NSCLC TACTI-002/KEYNOTE-798: 1st Line Non-Small Cell Lung Cancer (Part A) TACTI-002: Two ACTive Immunotherapeutics in NSCLC & HNSCC Baseline characteristics for PD-L1 All Comer Trial Part A (N=114) Age, median (range),
Slide 13: Compelling Clinical Results
Compelling Clinical Results TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) SITC 2022 Oral Presentation (Late-Breaking Abstract was among nine abstracts, out of +1,500 submissions, to be showcased at the SITC press briefing) TACTI-002 Phase II (1L NSCLC) Clinical Data and Key Takeaways • Primary objective
Slide 14: Strong, Differentiated Duration of Response
Strong, Differentiated Duration of Response TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) 2, 3 Interim Median Duration of Response (DoR) Tumor Burden Reduced in Majority of Patients 100 100 DoR by iRECIST (N=40) (%) (%) 90 75 Events, n (%) 10 (25.0) Best % change from baseline 80 Response 50 70 Median, m
Slide 15: Benchmarking against Pembrolizumab Monotherapy
Benchmarking against Pembrolizumab Monotherapy: Robust ORR/PFS Across Entire PD-L1 Spectrum vs Pembrolizumab TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Overall Response Rate* (ORR) Median Progression Free Survival# (PFS) (with 95% confidence interval) (by PD-L1 TPS Score) MedianPembrolizumab Progressi
Slide 16: Benchmarking against Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in 1L NSCLC
Benchmarking against Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in 1L NSCLC TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) ORR PFS DoR Efti + pembrolizumab High High High* Pembrolizumab Low Low High* Pembrolizumab + chemo High High Low *Note 34% patients in TACTI-002 have PD-L1 T
Slide 17: IO + IO + Chemo Combination Trial (INSIGHT-003)
IO + IO + Chemo Combination Trial (INSIGHT-003) INSIGHT-003: Phase I in Solid Tumors Focusing on NSCLC Adenocarcinomas INSIGHT-003 - Third arm (Stratum C) of investigator-initiated Initial Efficacy study in metastatic 1st Line NSCLC patients Tumor Response according to RECIST 1.1 (N=11) Complete Res
Slide 18: Additional Clinical Indications with Efti and Anti-PD-(L)1 Therapy or Chemotherapy
Additional Clinical Indications with Efti and Anti-PD-(L)1 Therapy or Chemotherapy Efti Late-Stage Clinical Development Head and Neck Squamous Cell Carcinoma (HNSCC) – There are ~900K cases and >400K deaths per annum in HNSCC1 – Pembrolizumab (KEYTRUDA®) with chemotherapy is approved for 1st line HN
Slide 19: Ongoing Randomized Phase IIb Trial in 1L HNSCC (Fast Track Status)
Ongoing Randomized Phase IIb Trial in 1L HNSCC (Fast Track Status) TACTI-003: Phase IIb in 1st Line Head and Neck Squamous Cell Carcinoma (1L HNSCC) TACTI-003 - Randomized Phase IIb Trial in 1L HNSCC patients utilizing Large Potential Opportunity for Chemo-Free Therapy with Efti + pembrolizumab vs.
Slide 20: Phase II/III Trial Underway in Metastatic Breast Cancer (MBC)
Phase II/III Trial Underway in Metastatic Breast Cancer (MBC): Efti Well Positioned to Enhance Standard-of-Care Chemotherapy AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ MBC Phase IIb Trial AIPAC: Multicenter, placebo-controlled, double-blind, 1:1 Statistically-Significant Increase of Cytoto
Slide 21: Efti + Anti-PD-L1 (Avelumab) in Urothelial Cancer & Advanced Solid Tumors
Efti + Anti-PD-L1 (Avelumab) in Urothelial Cancer & Advanced Solid Tumors INSIGHT-004: Phase I in Various Advanced Solid Tumors & INSIGHT-005: Phase I in Metastatic Urothelial Cancer INSIGHT-004 – Phase I dose escalation study in advanced INSIGHT-005 - Phase I study in metastatic urothelial solid tu
Slide 22: LAG-3 Immunotherapy for Autoimmune Diseases
LAG-3 Immunotherapy for Autoimmune Diseases
Slide 23: Targeting the Causes of Autoimmune Diseases
Targeting the Causes of Autoimmune Diseases Present Approaches Target Symptoms of Autoimmune Diseases Inhibitory receptor agonists: the future of Corticoids, methotrexate, TNF & interleukin autoimmune disease therapeutics? inhibitors (anti-TNF-α,-IL-6, -IL-17, -IL-23 mAbs) Future Approaches Target C
Slide 24: IMP761: First-in-Class LAG-3 Agonist is Potential Game-Changer
IMP761: First-in-Class LAG-3 Agonist is Potential Game-Changer As the world’s first immunosuppressive agonist antibody to LAG-3 acting upstream on activated T cells, IMP761 targets the root cause of many autoimmune diseases and represents a potential game-changer in the treatment landscape. Initiati
Slide 25: Board and Management
Board and Management Dr Russel Howard Pete Meyers Lucy Turnbull, AO Marc Voigt Prof. Frédéric Triebel, MD Ph.D. Deanne Miller Non-Executive Chairman Deputy Chairman Non-Executive Director Executive Director & CEO Executive Director, CSO & CMO COO, General Counsel Dr Howard has over 45 years Mr Meyer
Slide 26: Achievements & Upcoming Milestones
Achievements & Upcoming Milestones 2022 2023 • Fast Track designation granted in 1L NSCLC • Top-line readout from randomized TACTI-003 Phase IIb trial and • Industry conference presentations on efti trials: data updates during 2023 • ASCO - Oral Presentation in 1L NSCLC • SITC - Late-Breaking Abstra
Slide 27: Thank You
: =) Iimmutep Thank You